Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment
Information source: University Medical Center Groningen
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Failure; Kidney Failure
Intervention: Aliskiren (Drug); Placebo (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: University Medical Center Groningen
Summary
The main purpose of this study is to examine the effect of add-on therapy with the direct
renin inhibitor Aliskiren in comparison to placebo on renal blood flow in patients with
heart failure and reduced renal function.
- Primary outcome measure: change in renal blood flow at 6 months
- Secondary outcome measures: changes in renal function, N-terminal pro Brain natriuretic
peptide, left ventricular function, blood pressure and neurohormones
Clinical Details
Official title: A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Change in renal blood flow as assessed by 131I-Hippuran clearance
Secondary outcome: change in glomerular filtration rate (GFR) as assessed by 125I-IothalamateChange in systolic and diastolic blood pressure change in N-terminal pro brain natriuretic peptide levels (NT-proBNP) Change in left ventricular ejection fraction change in NYHA class, change in filtration fraction, change in albumin excretion, change in tubular function parameters, change in neurohormonal activation
Detailed description:
This study is a randomized, double-blind, placebo controlled, parallel group comparison
trial, enrolling 100 patients (67 vs. 33) with stable CHF. Patients will be randomized to
Aliskiren 300 mg once daily or corresponding Placebo for a period of 6 months. Efficacy
measures will be performed at baseline and at the end of the study. Primary efficacy outcome
is change in renal blood flow as measured by 131I-Hippuran clearance. Secondary outcome
include change in renal function, neurohormones, left ventricular function and blood
pressure. Safety assessments include renal function, changes in electrolytes, and blood
pressure. Patients will be uptitrated to maximum tolerated doses of Aliskiren, and safety
visits are planned 1 week after initiation and on a 2 month interval afterwards. A total of
8 visits are planned during the entire study period.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- NYHA II-IV Heart Failure
- Left ventricular ejection fraction < 45%
- Stable heart failure medication
- eGFR by sMDRD formula between 30 and 60 mL/min/1. 73m2
Exclusion Criteria:
- Known hypersensitivity to study drug or ACEi
- Concomitant treatment with both ARB and Aldosterone Receptor Antagonist
- Symptomatic Hypotension
- Acute Heart Failure
- History of stroke, acute coronary syndrome, PCI or angioplasty within past 3 months
- Serum potassium > 5. 2 mmol/L
- Right heart failure due to severe pulmonary disease
- Other protocol-defined inclusion/exclusion criteria may apply
Locations and Contacts
University Medical Center Groningen, Groningen, Netherlands
Additional Information
Related publications: McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17-24. doi: 10.1161/CIRCHEARTFAILURE.107.740704.
Starting date: April 2009
Last updated: May 16, 2013
|